Prenetics to Exit Bitcoin Holdings and Reinvest Up to $40 Million in Core IM8 Health Business

Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Prenetics Group ( (PRE) ) has issued an announcement. On May 1, 2026, Prenetics’ board approved the complete divestment of the company’s entire treasury position of about 510 Bitcoin, targeting completion of the sale by May 14, 2026 through institutional channels. Based on recent market prices, the company estimates roughly $40 million in gross proceeds, though the final amount will depend on Bitcoin price movements and execution costs during the sale period. The board also adopted a policy ruling out any future purchases of Bitcoin or other digital assets, signaling a definitive shift away from crypto holdings. Management said capital will be redeployed toward IM8, which is operating at scale and targeting full-year FY2026 revenue of $180 million to $200 million as Prenetics backs its highest-conviction growth asset. Proceeds from the divestment are earmarked to potentially expand a previously authorized $40 million share repurchase program, increase direct-to-consumer marketing for IM8, support new product launches in late 2026, and deepen IM8’s international market penetration. As of March 31, 2026, Prenetics held about $112 million in cash and liquid investments, and post-sale it expects to hold roughly $145 million to $150 million with no debt, strengthening its balance sheet. The company plans to report selected first-quarter FY2026 results on May 14, 2026, when it expects all Bitcoin sales to have been completed and final proceeds disclosed. Any realized gain or loss from the divestment will be reflected in its unaudited financial statements for the quarter ending June 30, 2026, giving investors greater clarity on the financial impact of exiting digital assets. The most recent analyst rating on (PRE) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page. Spark’s Take on PRE Stock According to Spark, TipRanks’ AI Analyst, PRE is a Neutral. The score is driven by strong technical uptrend signals and a bullish earnings-call outlook with robust growth/margin targets and solid liquidity. These positives are tempered by weak underlying financial performance—continued losses and cash burn—and a valuation profile that offers limited support due to negative earnings. To see Spark’s full report on PRE stock, click here. More about Prenetics Group Prenetics Global Limited is a Hong Kong–based consumer health company listed on Nasdaq under the ticker PRE. Its core operations center on IM8, a flagship direct-to-consumer health brand that sells wellness and health-related products globally, with an expanding presence in over 40 countries and a focus on digital marketing and product pipeline growth. Average Trading Volume: 229,802 Technical Sentiment Signal: Buy Current Market Cap: $286.4M See more data about PRE stock on TipRanks’ Stock Analysis page.